These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 26084206)

  • 1. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells.
    Fernández-Rodríguez C; Salar A; Navarro A; Gimeno E; Pairet S; Camacho L; Ferraro M; Serrano S; Besses C; Bellosillo B; Sanchez-Gonzalez B
    Leuk Lymphoma; 2016; 57(3):692-9. PubMed ID: 26084206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
    Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
    J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ricolinostat, a selective HDAC6 inhibitor, shows anti-lymphoma cell activity alone and in combination with bendamustine.
    Cosenza M; Civallero M; Marcheselli L; Sacchi S; Pozzi S
    Apoptosis; 2017 Jun; 22(6):827-840. PubMed ID: 28315173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.
    Lee JH; Choy ML; Ngo L; Foster SS; Marks PA
    Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14639-44. PubMed ID: 20679231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combinatorial epigenetic therapy in diffuse large B cell lymphoma pre-clinical models and patients.
    Pera B; Tang T; Marullo R; Yang SN; Ahn H; Patel J; Elstrom R; Ruan J; Furman R; Leonard J; Cerchietti L; Martin P
    Clin Epigenetics; 2016; 8():79. PubMed ID: 27453763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorinostat-induced apoptosis in mantle cell lymphoma is mediated by acetylation of proapoptotic BH3-only gene promoters.
    Xargay-Torrent S; López-Guerra M; Saborit-Villarroya I; Rosich L; Campo E; Roué G; Colomer D
    Clin Cancer Res; 2011 Jun; 17(12):3956-68. PubMed ID: 21652541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A model of sensitivity and resistance to histone deacetylase inhibitors in diffuse large B cell lymphoma: Role of cyclin-dependent kinase inhibitors.
    Tula-Sanchez AA; Havas AP; Alonge PJ; Klein ME; Doctor SR; Pinkston W; Glinsmann-Gibson BJ; Rimsza LM; Smith CL
    Cancer Biol Ther; 2013 Oct; 14(10):949-61. PubMed ID: 23982416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Kramer L; Fisher RI; Friedberg J; Dent P; Grant S
    Blood; 2010 Jun; 115(22):4478-87. PubMed ID: 20233973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.
    Xu J; Sampath D; Lang FF; Prabhu S; Rao G; Fuller GN; Liu Y; Puduvalli VK
    J Neurooncol; 2011 Nov; 105(2):241-51. PubMed ID: 21598070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumour activity of AMG 900 alone or in combination with histone deacetylase inhibitor SaHa on medulloblastoma cell lines.
    Geron L; Borges KS; Andrade AF; Suazo VK; Scrideli CA; Tone LG
    Neurol Res; 2015 Aug; 37(8):703-11. PubMed ID: 26000978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53-independent epigenetic repression of the p21(WAF1) gene in T-cell acute lymphoblastic leukemia.
    Davies C; Hogarth LA; Dietrich PA; Bachmann PS; Mackenzie KL; Hall AG; Lock RB
    J Biol Chem; 2011 Oct; 286(43):37639-50. PubMed ID: 21903579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a histone deacetylase 6 inhibitor and its biological effects.
    Lee JH; Mahendran A; Yao Y; Ngo L; Venta-Perez G; Choy ML; Kim N; Ham WS; Breslow R; Marks PA
    Proc Natl Acad Sci U S A; 2013 Sep; 110(39):15704-9. PubMed ID: 24023063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combining histone deacetylase inhibitor vorinostat with aurora kinase inhibitors enhances lymphoma cell killing with repression of c-Myc, hTERT, and microRNA levels.
    Kretzner L; Scuto A; Dino PM; Kowolik CM; Wu J; Ventura P; Jove R; Forman SJ; Yen Y; Kirschbaum MH
    Cancer Res; 2011 Jun; 71(11):3912-20. PubMed ID: 21502403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first-in-class alkylating deacetylase inhibitor molecule tinostamustine shows antitumor effects and is synergistic with radiotherapy in preclinical models of glioblastoma.
    Festuccia C; Mancini A; Colapietro A; Gravina GL; Vitale F; Marampon F; Delle Monache S; Pompili S; Cristiano L; Vetuschi A; Tombolini V; Chen Y; Mehrling T
    J Hematol Oncol; 2018 Feb; 11(1):32. PubMed ID: 29486795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway.
    Sarfstein R; Bruchim I; Fishman A; Werner H
    PLoS One; 2011; 6(9):e24468. PubMed ID: 21931726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
    Palmieri D; Lockman PR; Thomas FC; Hua E; Herring J; Hargrave E; Johnson M; Flores N; Qian Y; Vega-Valle E; Taskar KS; Rudraraju V; Mittapalli RK; Gaasch JA; Bohn KA; Thorsheim HR; Liewehr DJ; Davis S; Reilly JF; Walker R; Bronder JL; Feigenbaum L; Steinberg SM; Camphausen K; Meltzer PS; Richon VM; Smith QR; Steeg PS
    Clin Cancer Res; 2009 Oct; 15(19):6148-57. PubMed ID: 19789319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
    Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
    Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Kalac M; Scotto L; Marchi E; Amengual J; Seshan VE; Bhagat G; Ulahannan N; Leshchenko VV; Temkin AM; Parekh S; Tycko B; O'Connor OA
    Blood; 2011 Nov; 118(20):5506-16. PubMed ID: 21772049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trichostatin A effectively induces apoptosis in chronic lymphocytic leukemia cells via inhibition of Wnt signaling and histone deacetylation.
    Peiffer L; Poll-Wolbeck SJ; Flamme H; Gehrke I; Hallek M; Kreuzer KA
    J Cancer Res Clin Oncol; 2014 Aug; 140(8):1283-93. PubMed ID: 24793644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The synergistic effect of BCR signaling inhibitors combined with an HDAC inhibitor on cell death in a mantle cell lymphoma cell line.
    Hagiwara K; Kunishima S; Iida H; Miyata Y; Naoe T; Nagai H
    Apoptosis; 2015 Jul; 20(7):975-85. PubMed ID: 25835755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.